Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13701 - 13725 of 13815 in total
Tantalum has been investigated for the treatment and prevention of Osteoarthritis, Knee Osteoarthritis, Intraoperative Bleeding, and Adolescent Idiopathic Scoliosis.
Investigational
Matched Description: … Tantalum has been investigated for the treatment and prevention of Osteoarthritis, Knee Osteoarthritis …
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of
FB-101 is a c-Abl inhibitor. Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).
Experimental
Investigational
Matched Description: … Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders …
AMG-553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral vector.
Investigational
Matched Description: … 553 is an adoptive, anti-FLT3 chimeric antigen receptor T-cell therapy generated through transduction of
ARO-APOC3 is an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome.
Investigational
Matched Description: … It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome …
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
Matched Description: … Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in
Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.
Investigational
Matched Iupac: … 3-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-4-(1-methyl-1H-indol-5-yl)-4,5-dihydro-1H-1,2,4-triazol-5-one …
Matched Description: … Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid …
N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).
Investigational
Matched Description: … N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis …
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Matched Description: … Type 2 (ADO2). ... SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis …
RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.
Investigational
Matched Description: … RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal …
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Iupac: … 4-[(7R,7aS)-7-hydroxy-1,3-dioxo-hexahydro-1H-pyrrolo[1,2-c]imidazol-2-yl]-2-chloro-3-methylbenzonitrile …
Matched Description: … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause. …
TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]
Investigational
Matched Description: … TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear …
DCVAC/OvCa is a therapy comprising autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo. It is under investigation for the treatment of ovarian cancer.
Investigational
Matched Description: … It is under investigation for the treatment of ovarian cancer. …
Etamivan (INN) or ethamivan (USAN) is marketed under the name Analepticon. Etamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.
Withdrawn
Matched Description: … It is no longer used in the United States. …
Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Investigational
Matched Description: … Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO …
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Investigational
Matched Description: … MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to …
Dalcinonacog alfa is a recombinant human factor IX (FIX) variant. It is being investigated for the treatment of hemophilia B.
Investigational
Matched Description: … It is being investigated for the treatment of hemophilia B.[A259058] …
TTX-MC138 is an antisense oligonucleotide targeting miR-10b. It is under investigation for the treatment of various metastatic cancers.
Investigational
Matched Description: … [L48335] It is under investigation for the treatment of various metastatic cancers. …
tgAAVCF is an adeno-associated virus (AAV) vector encoding the human cystic fibrosis transmembrane conductance regulator protein (CFTR) cDNA. It is being investigated for the treatment of cystic fibrosis.[A259821, A259826]
Investigational
Matched Description: … It is being investigated for the treatment of cystic fibrosis.[A259821, A259826] …
A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Experimental
Matched Description: … A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial …
Dasiprotimut-T is a personalized therapeutic vaccine against B-cell lymphomas. It has been investigated in clinical trials.
Investigational
Matched Description: … [A254701] It has been investigated in clinical trials. …
ARO-ANG3 is a subcutaneously administered RNA interference (RNAi)-based investigational medicine targeting angiopoietin-like protein 3 (ANGPTL3). It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia (HoFH).
Investigational
Matched Description: … It was granted an orphan drug designation for the treatment of homozygous familial hypercholesterolemia …
CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.
Investigational
Matched Description: … [L48290] It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies …
Displaying drugs 13701 - 13725 of 13815 in total